Medical Device Investing 2010 and Beyond: Time To Challenge the Conventional Wisdom
This article was originally published in Start Up
A new analysis by Aisling Capital and Silicon Valley Bank questions the assumption that bets in medtech companies pay off more quickly and surely than biopharma investments. However, when medical device companies win, they win big.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.